Please assess the completion status of the following clinical trial:

Trial Title: Ginkgolide With Intravenous Alteplase Thrombolysis in Acute Ischemic Stroke Neurological Improving Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age over 18 years old, clinically diagnosed as acute ischemic stroke;~2. in accordance with the indications for intravenous thrombolysis;~3. The patient or family member signs an informed consent form.~Exclusion Criteria:~1. Patients with transient ischemic attack;~2. Imaging examination of patients with cerebral hemorrhage~3. patients with cerebral arteritis~4. ALT, AST ≥ 3 times the upper limit of normal value, Cr ≥ 1.5 times the upper limit of normal value~5. There is a tendency to bleed, and severe bleeding has occurred within 3 months~6. Patients with ginkgo drugs, alcohol, glycerol allergies or allergies~7. Patients with pregnancy plans, pregnancy and breastfeeding~8. Patients who participated in other drug clinical studies in the past month~9. Patients considered by the investigator to be unfit to participate in the clinical study (eg, mental, abnormal, etc.)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ginkgolide group (Type: EXPERIMENTAL): ginkgolide plus alteplase
- control (Type: NO_INTERVENTION): alteplase

Based on this trial design, predict the completion outcome and termination type (if applicable).